LRMR

Larimar Therapeutics Inc

LRMR, USA

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

https://larimartx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LRMR
stock
LRMR

Larimar Therapeutics Executes Strategic Stock Exchange Agreement TipRanks

Read more →
LRMR
stock
LRMR

Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl Investing.com UK

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$16.7

Analyst Picks

Strong Buy

10

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.12

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-34.32 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-25.47 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.35

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 72.94% of the total shares of Larimar Therapeutics Inc

1.

Deerfield Management Co

(24.8065%)

since

2025/06/30

2.

RA Capital Management, LLC

(7.0631%)

since

2025/06/30

3.

Blue Owl Capital Holdings LP

(5.7577%)

since

2025/06/30

4.

Opaleye Management Inc

(4.8019%)

since

2025/06/30

5.

Millennium Management LLC

(4.2706%)

since

2025/06/30

6.

BlackRock Inc

(3.5518%)

since

2025/06/30

7.

Vanguard Group Inc

(2.5027%)

since

2025/06/30

8.

Alyeska Investment Group, L.P.

(2.4254%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.2792%)

since

2025/07/31

10.

Citadel Advisors Llc

(1.5612%)

since

2025/06/30

11.

Two Sigma Advisers, LLC

(1.34%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(1.2496%)

since

2025/08/31

13.

Geode Capital Management, LLC

(1.0567%)

since

2025/06/30

14.

Two Sigma Investments LLC

(1.0557%)

since

2025/06/30

15.

State Street Corp

(1.0036%)

since

2025/06/30

16.

Mangrove Partners

(0.8999%)

since

2025/06/30

17.

Caption Management, LLC

(0.8053%)

since

2025/06/30

18.

Woodline Partners LP

(0.7275%)

since

2025/06/30

19.

Verition Fund Managegment, LLC

(0.6633%)

since

2025/06/30

20.

Renaissance Technologies Corp

(0.6563%)

since

2025/06/30

21.

Driehaus Capital Management LLC

(0.6256%)

since

2025/06/30

22.

AQR Capital Management LLC

(0.5006%)

since

2025/06/30

23.

Fidelity Small Cap Index

(0.4992%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.429%)

since

2025/08/31

25.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4095%)

since

2025/07/31

26.

iShares Biotechnology ETF

(0.2596%)

since

2025/08/31

27.

Vanguard Russell 2000 ETF

(0.2372%)

since

2025/07/31

28.

Fidelity Extended Market Index

(0.2023%)

since

2025/07/31

29.

State St Russell Sm Cap® Indx SL Cl I

(0.1633%)

since

2025/08/31

30.

CREF Stock R3

(0.1423%)

since

2025/07/31

31.

Schwab Small Cap Index

(0.1302%)

since

2025/07/31

32.

NT R2000 Index Fund - NL

(0.1206%)

since

2025/06/30

33.

Bridgeway Ultra-Small Company Market

(0.1132%)

since

2025/06/30

34.

iShares Micro-Cap ETF

(0.113%)

since

2025/08/31

35.

NT R2000 Index Fund - DC - NL - 3

(0.0962%)

since

2025/06/30

36.

Avantis US Small Cap Equity ETF

(0.0912%)

since

2025/08/30

37.

Extended Equity Market Fund K

(0.086%)

since

2025/06/30

38.

SPDR® Russell 2000 US Small Cap ETF

(0.0835%)

since

2025/08/31

39.

iShares Russell 2000 Small-Cap Idx Instl

(0.0819%)

since

2025/07/31

40.

Russell 2500â„¢ Index Fund F

(0.0805%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4142

Latest Release

Date

2025-09-30

EPS Actual

-0.61

EPS Estimate

-0.4128

EPS Difference

-0.1972

Surprise Percent

-47.7713%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.